Testani Erica, Latta Kristen, Barker Emily, York Sloane L, Laursen Laura
From the Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, Illinois, USA.
Int J Gynaecol Obstet. 2023 Jan;160(1):145-149. doi: 10.1002/ijgo.14302. Epub 2022 Jul 15.
To assess complication rates of patients undergoing a second-trimester medical termination for intrauterine fetal demise compared with fetal anomalies.
We performed a retrospective cohort study comparing patients undergoing medical termination for a fetal anomaly versus medical termination for intrauterine fetal demise (IUFD) before 24 weeks of gestation. Data were collected from two urban academic medical centers from 2009 to 2019. Institutional review board approval was obtained from both institutions and patient consent was not required. We included singleton gestations between 14.0 weeks and 23.6 weeks undergoing induction with mifepristone and misoprostol or misoprostol alone. Groups were matched based on gestational age with a 1:1 ratio. The primary outcome was composite complication rate (retained placenta requiring dilation and curettage, suspected infection, hemorrhage, failed induction requiring dilation and evacuation, intensive care unit admission, and readmission).
Ninety-five patients were in each group. The groups differed in patient mean age (fetal anomaly 34 years versus 31 years for IUFD, P = 0.005) and mifepristone pretreatment (fetal anomaly 55% versus IUFD 5%, P < 0.001). Composite complication rate was similar (fetal anomaly 14% versus IUFD 17%), and specific complications did not differ.
Second-trimester medical termination for IUFDs have similar complication rates as those undergoing induction terminations for fetal anomalies.
评估与因胎儿畸形而行孕中期药物引产的患者相比,因胎儿宫内死亡而行孕中期药物引产的患者的并发症发生率。
我们进行了一项回顾性队列研究,比较了因胎儿畸形而行药物引产的患者与妊娠24周前因胎儿宫内死亡(IUFD)而行药物引产的患者。数据收集自2009年至2019年的两家城市学术医疗中心。两个机构均获得了机构审查委员会的批准,且无需患者同意。我们纳入了孕14.0周至23.6周的单胎妊娠,这些妊娠采用米非司酮和米索前列醇或仅米索前列醇引产。根据孕周以1:1的比例对两组进行匹配。主要结局是综合并发症发生率(需要刮宫术处理的胎盘残留、疑似感染、出血、引产失败需要扩张刮宫术、入住重症监护病房和再次入院)。
每组各有95例患者。两组患者的平均年龄不同(胎儿畸形组为34岁,IUFD组为31岁,P = 0.005),米非司酮预处理情况也不同(胎儿畸形组为55%,IUFD组为5%,P < 0.001)。综合并发症发生率相似(胎儿畸形组为14%,IUFD组为17%),具体并发症无差异。
因IUFD而行孕中期药物引产的患者与因胎儿畸形而行引产的患者并发症发生率相似。